Tau-aggregation inhibitor therapy for Alzheimer's disease
Author:
Publisher
Elsevier BV
Subject
Pharmacology,Biochemistry
Reference102 articles.
1. Alzheimer's disease: clinical trials and drug development;Mangialasche;Lancet Neurol,2010
2. Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond;Mullane;Biochem Pharmacol,2013
3. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial;Holmes;Lancet,2008
4. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force;Vellas;Alzheimers Dement,2013
5. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial;Wilcock;Lancet Neurol,2008
Cited by 221 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Atomic insights into the inhibition of R3 domain of tau protein by epigallocatechin gallate, quercetin and gallic acid;Biophysical Chemistry;2024-02
2. Current trends and updates in the treatment of Alzheimer's disease;Alzheimer's Disease and Advanced Drug Delivery Strategies;2024
3. Targets, trials and tribulations in Alzheimer therapeutics;European Journal of Pharmacology;2024-01
4. miR-519a-3p, found to regulate cellular prion protein during Alzheimer’s disease pathogenesis, as a biomarker of asymptomatic stages;2023-12-15
5. Gene therapy: an alternative to treat Alzheimer’s disease;Naunyn-Schmiedeberg's Archives of Pharmacology;2023-12-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2023 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3